1. Home
  2. IMMP vs PPT Comparison

IMMP vs PPT Comparison

Compare IMMP & PPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMMP
  • PPT
  • Stock Information
  • Founded
  • IMMP 1987
  • PPT 1988
  • Country
  • IMMP Australia
  • PPT United States
  • Employees
  • IMMP N/A
  • PPT N/A
  • Industry
  • IMMP Biotechnology: Pharmaceutical Preparations
  • PPT Finance Companies
  • Sector
  • IMMP Health Care
  • PPT Finance
  • Exchange
  • IMMP Nasdaq
  • PPT Nasdaq
  • Market Cap
  • IMMP 304.0M
  • PPT 348.9M
  • IPO Year
  • IMMP N/A
  • PPT N/A
  • Fundamental
  • Price
  • IMMP $1.92
  • PPT $3.62
  • Analyst Decision
  • IMMP Buy
  • PPT
  • Analyst Count
  • IMMP 2
  • PPT 0
  • Target Price
  • IMMP $8.50
  • PPT N/A
  • AVG Volume (30 Days)
  • IMMP 72.2K
  • PPT 156.1K
  • Earning Date
  • IMMP 03-03-2025
  • PPT 01-01-0001
  • Dividend Yield
  • IMMP N/A
  • PPT 8.84%
  • EPS Growth
  • IMMP N/A
  • PPT N/A
  • EPS
  • IMMP N/A
  • PPT N/A
  • Revenue
  • IMMP $2,563,302.00
  • PPT N/A
  • Revenue This Year
  • IMMP N/A
  • PPT N/A
  • Revenue Next Year
  • IMMP $47.79
  • PPT N/A
  • P/E Ratio
  • IMMP N/A
  • PPT N/A
  • Revenue Growth
  • IMMP 9.59
  • PPT N/A
  • 52 Week Low
  • IMMP $1.66
  • PPT $3.25
  • 52 Week High
  • IMMP $3.34
  • PPT $3.72
  • Technical
  • Relative Strength Index (RSI)
  • IMMP 43.56
  • PPT 54.52
  • Support Level
  • IMMP $1.94
  • PPT $3.56
  • Resistance Level
  • IMMP $2.08
  • PPT $3.61
  • Average True Range (ATR)
  • IMMP 0.08
  • PPT 0.03
  • MACD
  • IMMP -0.00
  • PPT 0.00
  • Stochastic Oscillator
  • IMMP 20.00
  • PPT 66.67

About IMMP Immutep Limited

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.

About PPT Putnam Premier Income Trust

Putnam Premier Income Trust is a Massachusetts business trust operating as a non-diversified closed-end management investment company. The fund is currently operating as a diversified fund. Its investment objective is to seek high current income consistent with the preservation of capital by allocating its investments to the U.S. government sector.

Share on Social Networks: